The COVID-19 Vaccines: Recent Development, Challenges and Prospects.
COVID-19
SARS-CoV-2
coronavirus
global pandemic
vaccines
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
05 Apr 2021
05 Apr 2021
Historique:
received:
04
03
2021
revised:
21
03
2021
accepted:
22
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
The highly infectious coronavirus disease 2019 (COVID-19) associated with the pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to become a global pandemic. At present, the world is relying mainly on containment and hygiene-related measures, as well as repurposed drugs to control the outbreak. The development of COVID-19 vaccines is crucial for the world to return to pre-pandemic normalcy, and a collective global effort has been invested into protection against SARS-CoV-2. As of March 2021, thirteen vaccines have been approved for application whilst over 90 vaccine candidates are under clinical trials. This review focuses on the development of COVID-19 vaccines and highlights the efficacy and vaccination reactions of the authorised vaccines. The mechanisms, storage, and dosage specification of vaccine candidates at the advanced stage of development are also critically reviewed together with considerations for potential challenges. Whilst the development of a vaccine is, in general, in its infancy, current progress is promising. However, the world population will have to continue to adapt to the "new normal" and practice social distancing and hygienic measures, at least until effective vaccines are available to the general public.
Identifiants
pubmed: 33916489
pii: vaccines9040349
doi: 10.3390/vaccines9040349
pmc: PMC8067284
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Ningbo Municipal Bureau of Science and Technology
ID : 2018B10022
Organisme : Ningbo Municipal Bureau of Science and Technology
ID : 2018A610069
Organisme : Science and Technology Department of Zhejiang Province
ID : 2020E10018
Références
Engineering (Beijing). 2020 Oct;6(10):1192-1198
pubmed: 32346491
Science. 2020 Jul 3;369(6499):77-81
pubmed: 32376603
Front Immunol. 2020 Oct 14;11:585354
pubmed: 33163000
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
Lancet. 2020 Feb 29;395(10225):689-697
pubmed: 32014114
N Engl J Med. 2003 Dec 18;349(25):2468-9
pubmed: 14681520
Science. 2020 May 29;368(6494):1016-1020
pubmed: 32269068
Microorganisms. 2020 Nov 23;8(11):
pubmed: 33238451
Nature. 2020 Mar;579(7798):183
pubmed: 32152596
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
JAMA. 2020 Sep 8;324(10):951-960
pubmed: 32789505
Int J Environ Res Public Health. 2020 Mar 30;17(7):
pubmed: 32235575
BMJ. 2020 Dec 23;371:m4944
pubmed: 33361120
J Med Virol. 2020 Apr;92(4):455-459
pubmed: 31994738
Immun Ageing. 2006 Feb 24;3:2
pubmed: 16504129
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
Nanoscale. 2020 Aug 21;12(31):16409-16413
pubmed: 32725017
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Materials (Basel). 2020 Nov 26;13(23):
pubmed: 33255977
Eur J Clin Invest. 2020 Mar;50(3):e13209
pubmed: 32003000
Nature. 2020 Oct;586(7830):509-515
pubmed: 32967005
Vaccine. 2009 Aug 6;27(36):5001-7
pubmed: 19523911
Emerg Microbes Infect. 2022 Dec;11(1):1058-1071
pubmed: 35311493
Viruses. 2021 Mar 09;13(3):
pubmed: 33803400
Front Pharmacol. 2021 Sep 02;12:683296
pubmed: 34539392
F1000Res. 2020 Feb 21;9:129
pubmed: 32194944
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
Nature. 2021 Feb;590(7845):191-192
pubmed: 33547430
Lancet. 2020 Sep 26;396(10255):887-897
pubmed: 32896291
Vaccine. 2021 Aug 9;39(34):4885-4894
pubmed: 34253420
Vaccine. 2020 Mar 23;38(14):2943-2948
pubmed: 32107060
J Biol Chem. 2020 Apr 10;295(15):4773-4779
pubmed: 32094225
Int J Mol Sci. 2020 Dec 21;21(24):
pubmed: 33371468
Sci Adv. 2020 Aug 14;6(33):eabc1202
pubmed: 32851189
J Microbiol Immunol Infect. 2020 Jun;53(3):436-443
pubmed: 32307245
BMJ. 2020 Nov 20;371:m4552
pubmed: 33219049
Travel Med Infect Dis. 2021 Mar-Apr;40:101989
pubmed: 33578045
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Microbes Infect. 2020 Jul - Aug;22(6-7):245-253
pubmed: 32437926
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Immun Ageing. 2020 Apr 11;17:8
pubmed: 32300370
J Med Virol. 2020 Jun;92(6):548-551
pubmed: 32096567
J Clin Med. 2020 Feb 01;9(2):
pubmed: 32024089
China CDC Wkly. 2020 Feb 21;2(8):113-122
pubmed: 34594836
Nat Rev Immunol. 2020 Nov;20(11):650
pubmed: 32989290
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
Aust Prescr. 2021 Feb;44(1):19-25
pubmed: 33664546
BMJ. 2020 Nov 11;371:m4362
pubmed: 33177042
Nature. 2004 Apr 1;428(6982):561-4
pubmed: 15024391
Viral Immunol. 2012 Feb;25(1):55-62
pubmed: 22225471
Mayo Clin Proc. 2020 Oct;95(10):2172-2188
pubmed: 33012348
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Br J Anaesth. 2021 Mar;126(3):e106-e108
pubmed: 33386124
Respirology. 2003 Sep;8(3):259-65
pubmed: 14528875
Vaccines (Basel). 2014 Jul 29;2(3):624-41
pubmed: 26344749
Osong Public Health Res Perspect. 2020 Dec;11(6):343-344
pubmed: 33403196
Lancet. 2020 Nov 14;396(10262):1595-1606
pubmed: 33065034
ACS Nano. 2020 Apr 28;14(4):3822-3835
pubmed: 32223179
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Infect Genet Evol. 2020 Apr;79:104211
pubmed: 32007627
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480
Hum Gene Ther. 2020 Jun;31(11-12):605-607
pubmed: 32469280